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ABSTRACT
Background: Zinc deficiency impairs immune function and is common among children in South-East Asia.
Objectives: The effect of zinc supplementation on immune function in young Laotian children was investigated.
Methods: Children (n = 512) aged 6–23 mo received daily preventive zinc tablets (PZ; 7 mg Zn/d), daily multiple
micronutrient powder (MNP; 10 mg Zn/d, 6 mg Fe/d, plus 13 other micronutrients), therapeutic dispersible zinc tablets
only in association with diarrhea episodes (TZ; 20 mg Zn/d for 10 d after an episode), or daily placebo powder (control).
These interventions continued for 9 mo. Cytokine production from whole blood cultures, the concentrations of T-cell
populations, and a complete blood count with differential leukocyte count were measured at baseline and endline.
Endline means were compared via ANCOVA, controlling for the baseline value of the outcome, child age and sex, district,
month of enrollment, and baseline zinc status (below, or above or equal to, the median plasma zinc concentration).
Results: T-cell cytokines (IL-2, IFN-γ , IL-13, IL-17), LPS-stimulated cytokines (IL-1β, IL-6, TNF-α, and IL-10), and T-cell
concentrations at endline did not differ between intervention groups, nor was there an interaction with baseline zinc
status. However, mean ± SE endline lymphocyte concentrations were significantly lower in the PZ than in the control
group (5018 ± 158 compared with 5640 ± 160 cells/μL, P = 0.032). Interactions with baseline zinc status were seen for
eosinophils (Pixn = 0.0036), basophils (Pixn = 0.023), and monocytes (P = 0.086) but a significant subgroup difference
was seen only for eosinophils, where concentrations were significantly lower in the PZ than in the control group among
children with baseline plasma zinc concentrations below the overall median (524 ± 44 compared with 600 ± 41 cells/μL,
P = 0.012).
Conclusions: Zinc supplementation of rural Laotian children had no effect on cytokines or T-cell concentrations,
although zinc supplementation affected lymphocyte and eosinophil concentrations. These cell subsets may be useful
as indicators of response to zinc supplementation. This trial was registered at clinicaltrials.gov as NCT02428647. J Nutr
2020;00:1–10.
Keywords: zinc supplementation, children, cytokine production, T-cell concentration, complete blood count
Introduction
Zinc is an important nutrient for maintaining homeostasis of
the immune system and zinc deficiency can impair immune
function (1).Zinc deficiency is associated with both an increased
risk and an increased severity of common childhood infections
such as diarrhea and pneumonia in lower-income countries
around the world (2), perhaps as a result of impaired immune
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function. Zinc is a transition metal that plays an important
role in the function of many proteins (e.g., as a cofactor in the
active site in enzymes, or as a constituent of zinc-finger motifs
in regulatory proteins that bind DNA). The observation that
∼10% of the proteins encoded in the human genome bind zinc
highlights the important role of zinc in many aspects of protein
function (3). In addition, intracellular zinc transporters may
allow rapid intracellular signaling in immune cells by facilitating
a flux of zinc ions between intracellular compartments and the
cytoplasm (4).
Previous studies in both murine and human primary mono-
cytes showed that zinc deficiency impairs Toll-like receptor
(TLR)-4-mediated signaling and thus diminishes the response to
bacterial LPS which generally stimulates phagocytic activity and
production of cytokines such as IL-1β, TNF-α, IL-6, and IL-10
(5, 6). Moreover, zinc deficiency causes thymic atrophy with
a substantial reduction of T-cell counts (7). Zinc deficiency
also impairs T-cell function, impairing T-cell receptor (TCR)
signaling (8) and thus decreasing T-cell proliferation and
cytokine production in response to signaling through the
TCR (9). Studies in humans have found that zinc deficiency
impairs the production of T-helper (Th) 1 cytokines (IL-2,
TNF-α, and IFN-γ ) while showing a lesser effect on the
production of Th2 cytokines (IL-4, IL-6, and IL-10) (10),
suggesting that zinc affects Th1/Th2 balance. Several studies
have reported that these dysregulations associated with low zinc
concentration are restored by zinc supplementation (10, 11). In
some cases, zinc treatment in vivo and in vitro shows regulatory
activity, dampening Th-cell-mediated immune responses (e.g.,
Th2 allergic responses and Th17 autoimmune responses), and
increases the number and activity of regulatory T (Treg) cells
(12, 13). These effects of zinc deficiency on immune functions
may be responsible, at least in part, for the increased risk of
infection (14).
Inadequate zinc status and zinc deficiency are estimated to
range from 7.5% in high-income regions to 30% in South
Asia (15). Undernutrition, including fetal growth restriction,
suboptimum breastfeeding, stunting, wasting, and deficiencies
of vitamin A and zinc, are an underlying cause of 45%
of child deaths, resulting in 3.1 million deaths annually
(16); 25% of these deaths are among infants and children
<5 y old (16). Multiple systematic reviews have reported
that preventive zinc supplementation is associated with a
decrease in diarrhea and pneumonia morbidity and mortality
in children in lower-income countries (17–19). The present
study was conducted as a substudy of immune function nested
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within a randomized controlled trial examining the optimal
zinc supplementation strategy for improving growth, diarrheal
morbidity, and hematologic and micronutrient status in rural
Laotian children at risk of zinc deficiency (20). The intervention
groups were supplementation with daily preventive zinc tablets
(PZ), daily multiple micronutrient powder (MNP) that included
zinc, use of supplementation with therapeutic dispersible zinc
tablets (TZ) for 10 d as part of treatment of diarrhea, and a
daily placebo (control). Children from 6–23 mo of age were
randomly assigned to receive these treatments for ∼9 mo in a
community-based intervention trial. As previously reported, the
parent study found no impact on growth and overall diarrhea
burden (21) but PZ and MNP increased plasma zinc relative to
the control and TZ groups (21).
In the present study, we hypothesized that innate and
adaptive immune defenses of these Laotian children would
be altered by zinc supplementation. To investigate the effect
of the interventions, we measured cytokine production from
whole blood cultures stimulatedwith bacterial LPS (an activator
of the innate immune system) or with TCR activation (to
stimulate these adaptive immune cells) at baseline and endline.
In addition, we measured the concentrations of total and
memory CD4 and CD8 T-cells, and Treg cells from whole
blood at the same time points. Finally, in a secondary analysis,
we performed a complete blood count (CBC) with an auto-
differential to measure lymphocyte, monocyte, neutrophil,
eosinophil, basophil, and platelet concentrations at baseline and
endline.
Methods
Study design and recruitment
This study is a substudy within a randomized, masked, community-
based trial in rural Lao People’s Democratic Republic (20, 21).
Briefly, this parent study aimed to determine the effects of 2 daily
zinc supplementation regimens—a therapeutic zinc supplementation
regimen for diarrhea, and a placebo intervention—on physical growth
and morbidity, including the risk of episodes of diarrhea, in young
children. In total 3407 children 6–23 mo of age were enrolled and
randomly assigned to 1 of 4 treatment groups. The children received
either 1) daily PZ supplements (7 mg Zn), 2) daily MNP (containing
10 mg Zn, 6 mg Fe, and 13 other vitamins and minerals), 3) 10 d
of TZ (containing 20 mg Zn) for episodes of diarrhea, or 4) daily
placebo (control) dispersible tablets as the negative control group. All
children not in the TZ group received placebo capsules in association
with diarrhea episodes rather than the zinc received in the TZ group.
The supplement regimen for the preventive supplements (PZ andMNP)
was daily for 9 mo, and therapeutic supplements (TZ) were provided
to be taken along with oral rehydration solution starting on the first
day of diarrhea for 10 d for episodes of diarrhea. The enrolled children
remained under observation for ∼36 wk, so the children’s ages ranged
from 15 to 32 mo at endline. Children were excluded if they met any of
the following criteria at baseline: weight-for-length z score (WLZ) < −3
SD, presence of bipedal edema, severe illness, congenital abnormalities,
chronic medical condition (e.g., malignancy), known HIV infection of
index child or child’s mother, severe anemia, current consumption of
zinc supplements, or current participation in any other clinical trial.
Infants included in the present substudy lived in 2 of the districts
closest to the laboratory used for blood processing (which allowed
reliable, same-day transport of samples from the field site to the
laboratory) and were enrolled on Monday through Thursday to
facilitate the studies of immune function. Enrollment of infants at
baseline was conducted between September and December 2015 and
the endline follow-up occurred from May to August 2016. At baseline,
samples from a total of 636 subjects were received at Nakonphanom
Hospital; CBC analysis was performed on 574 of these samples, whole
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blood cultures on 506, and flow cytometry analysis on 492, depending
on the volume of the blood sample available. Approximately 82%
of participants were re-examined at the follow-up visit. The present
analysis included only subjects for whom we had both baseline and
endline data.
The trial was approved by the National Ethics Committee for
Health Research,Ministry of Health, Lao People’s Democratic Republic
(040/2014, 069/2015, 039/2016); the University of California, Davis
Institutional Review Board (626187); and the Khon Kaen University,
Thailand Ethics Committee in Health Research (HE572312).
Anthropometry
Anthropometric assessments were recorded by trained data collectors
using standardized procedures at baseline and endline. Measurements
included weight to the nearest 0.02 kg and recumbent length to the
nearest 0.1 cm and means were determined from 2 measurements.
Length-for-age z scores (LAZs), weight-for-age z scores (WAZs), and
WLZs were calculated (22) and used to identify study participants with
stunting (LAZ < −2 SD) and underweight (WAZ < −2 SD). Children
who were severely wasted (WLZ < −3 SD) at baseline were excluded
from participation and referred to the nearest health center or hospital.
Maternal weights were measured to 0.05 kg precision and maternal
heights to 0.1 cm precision at baseline.
Blood collection, transport, and sample size
At baseline and endline blood was collected at the field site from
children using an antecubital, dorsal metacarpal, or saphenous vein
using techniques recommended by the International Zinc Nutrition
Consultative Group (23). Blood was first collected into trace element–
free 7.5-mL polyethylene blood collection tubes containing lithium
heparin (Sarstedt AG & Co; ref. 01.1604.400) for immune assays
and measurement of plasma zinc, C-reactive protein (CRP), and α-
1-acid glycoprotein (AGP) concentrations. Blood was then collected
into a trace element–free 1.2-mL polyethylene blood collection tube
containing EDTA (Sarstedt; ref. 06.1666.100), which was used for
a CBC with differential. Two-milliliter aliquots of heparinized whole
blood were immediately removed from the blood collection tube and
stored at 20–25◦C; EDTA-containing blood collection tubes were
stored at 4–8◦C; both samples were transported to the laboratory at
Nakonphanom Hospital in Thailand, where the laboratory tests on
peripheral blood were completed the same day (i.e., CBC with 5-
part automated differential, flow cytometry analysis of T-cell subsets,
and whole blood cultures to stimulate production of cytokines). The
remaining whole blood in the lithium heparin tube was stored at
4–8◦C until centrifugation at 4◦C for 10 min at 1,000 × g to
collect plasma. Plasma aliquots were stored at −20◦C before laboratory
analyses (i.e., plasma zinc, CRP, and AGP concentrations).
Blood cultures for cytokine production
Whole blood treated with heparin was used to set up whole blood
cultures in 96-well plates. The external wells contained 200 mL sterile
PBS to prevent excessive evaporation of experimental wells during the
culture. Blood was diluted 10-fold in RPMI 1640 cell-culture medium
(Gibco) and then 200 μL/well was treated with 1) 3 μg/mL plate-coated
anti-CD3 antibody plus anti-CD28 antibody in solution (eBioscience)
to stimulate T-cell cytokine production or 2) the same volume of
isotype control antibodies (eBioscience). Undiluted blood (final blood
dilution 1:2) was treated with 1) LPS from Escherichia coli 0111:B4
(List Biological Laboratories) at a final concentration of 20 μg/mL [in
pyrogen-free water (Sigma-Aldrich)] or only 2) RPMI, the diluent for
the working solution of LPS. All cells were cultured for 48 h at 37◦C in
a 5% CO2 atmosphere. Supernatants were collected and kept frozen at
−80◦C for later shipment on dry ice to the Western Human Nutrition
Research Center in Davis, CA, for cytokine analysis.
T-cell staining and flow cytometry analysis
In addition to preparing the blood cultures, surface staining of
lymphocytes in whole blood was performed using directly conjugated
antibodies, including PerCP anti-CD3, APC anti-CD4, FITC anti-CD8,
PE anti-CD45RO, FITC anti-CD25, and PE anti-CD127 (BD), and
AccuCount Fluorescence Beads (Spherotech) to determine absolute T-
cell concentrations. Two staining tubes were used.Tube 1 identified total
(CD3+) T-cells, CD4+ T-cells, CD8+ T-cells, and memory (CD45RO+)
CD4 and CD8 T-cells. Tube 2 was used to identify CD4+ Treg
cells (CD3+CD4+CD25+CD127low). The staining was performed
in Nakhonphanom. After fixation with paraformaldehyde, stained
samples were stored at 4◦C for ≤3 d before transportation at 4–10◦C to
Khon Kaen University (303 km over good, asphalt roads) for flow
cytometric analysis using a FACSCalibur flow cytometer (BD). Gating
was performed using FlowJo software (BD).
Measuring cytokines in supernatants from whole
blood cultures
Supernatants from whole blood cultures stimulated to activate T-
cells (and negative control supernatants) were analyzed for IL-2, IL-
10, IL-13, IL-17A, and IFN-γ , whereas LPS-stimulated (and negative
control) supernatants were analyzed for IL-1β, IL-6, IL-10, and
TNF-α. Cytokines were assayed using an electrochemiluminescence-
based detection platform with multiplexed immunoassays using the
U-PLEX system from MSD (Mesoscale Discovery, LLC). U-PLEX
plates were coated overnight at 4◦C with a complex of specific
linker for the corresponding spots and biotinylated Capture Antibody
under light shaking (600–800 rpm) overnight and kept for ≤7 d at
4◦C. Samples (final dilution 1:2 in Diluent 43) were also incubated
overnight at 4◦C (600–800 rpm). The next day, plates were incubated
after washing with 1× detection antibodies for 2 h at room temperature
under light shaking (600–800 rpm) and subsequently washed. After
adding 2× Readbuffer the plates were analyzed on an MSD instrument
(MESO QuickPlex SQ120, 4-parameter logistic curve).
CBC with 5-part differential
This analysis was performed following Nakhonphanom Hospital
laboratory protocols by an automated hematology analyzer (Sysmex,
XT-1800i). The analyzer provides a CBC and leukocyte 5-part differ-
ential on whole blood (including lymphocytes, monocytes, neutrophils,
eosinophils, and basophils). We were able to measure these variables
because the clinical laboratory in which we worked made these
measurements routinely.
Plasma analysis
Plasma zinc was analyzed by inductively coupled plasma optical
emission spectrophotometry (5100 ICP-OES SVDV,Agilent) at the Chil-
dren’s Hospital of Oakland Research Institute as described previously
(20, 21). CRP and AGP were measured using a combined sandwich
ELISA technique at the VitMin Laboratory (Willstaett, Germany), and
used to adjust plasma zinc concentrations for inflammation, as described
previously (21).
Statistical analysis
A statistical analysis plan was developed before analysis. Analyses
were conducted with SAS for Windows release 9.4 (SAS Institute).
Adjusted cytokine concentrations (i.e., adjusted concentration equals
concentration for the stimulated whole blood culture minus the
concentration for the negative control culture of the same sample)
were used for statistical comparisons. Nearly all adjusted cytokine
concentrations were positive (as expected) but 6 (5 for IL-10 at baseline
and 1 for IL-13 at endline) yielded a small negative number for the
adjusted value and these were changed to small positive numbers (0.1
for IL-10 and 1.0 for IL-13) for statistical analysis to allow for retaining
rank order and for ease of transformation, if needed. Descriptive
statistics were calculated for all variables, and extreme outliers were
identified and examined for possible removal. Such outliers were only
found with the flow cytometry data, where some samples at endline
(n = 5 for the T-cell collection tube, n = 17 for the Treg collection
tube, and n = 7 for both) had implausibly high counts of beads
(>20,000 per collection) or of CD3 T-cells (>10,000 cells/μL; usually
resulting from implausibly low bead counts of <1000 per collection),
presumably as a result of technical problems. These samples were
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TABLE 1 Baseline characteristics of total study population (All) and each treatment group1
Characteristic All Control TZ MNP PZ P value
Age, mo 15.6 ± 5.11 15.6 ± 5.12 15.6 ± 5.11 16.1 ± 4.97 15.3 ± 5.29 0.41
Males 52.3 (268) 55.2 (74) 50.0 (60) 53.7 (73) 50.0 (61) 0.78
LAZ2 − 1.67 ± 1.07 − 1.36 ± 1.06a − 1.79 ± 0.97b − 1.78 ± 1.04b − 1.76 ± 1.17b 0.0018
Stunting (LAZ < −2 SD)2 36.8 (188) 28.4 (38) 38.3 (46) 39.7 (54) 41.3 (50) 0.13
WAZ2 − 1.39 ± 0.99 − 1.11 ± 0.96a − 1.46 ± 0.96b − 1.47 ± 0.98 b − 1.53 ± 1.01b 0.0023
Underweight (WAZ < −2 SD)2 25.6 (131) 14.9 (20)a 26.7 (32)a,b 29.4 (40)b 32.2 (39)b 0.0096
WLZ2 − 0.73 ± 0.88 − 0.57 ± 0.84 − 0.74 ± 0.90 − 0.76 ± 0.84 − 0.8 ± 0.93 0.054
Wasting (WLZ < −2 SD)2 6.8 (35) 3.0 (4) 5.8 (7) 7.4 (10) 11.6 (14) 0.073
Maternal age,3 y 26.8 ± 6.07 26.5 ± 5.82 26.7 ± 6.03 27.7 ± 6.35 26.2 ± 6.02 0.29
Maternal BMI,4 kg/m2 21.8 ± 3.24 22.1 ± 3.75 21.5 ± 3.04 22.2 ± 3.12 21.5 ± 2.86 0.30
Plasma zinc,5 mg/dL 57.4 ± 11.9 56.6 ± 11.6 58.0 ± 11.1 58.4 ± 11.3 56.6 ± 13.4 0.26
Plasma zinc below median5 51.1 (261) 48.5 (65) 49.6 (59) 46.3 (63) 60.7 (74) 0.11
Plasma zinc < 65 mg/dL5 77.5 (396) 82.1 (110) 79.0 (94) 72.8 (99) 76.2 (93) 0.31
1Values are means ± SDs or % (n). Continuous variables were compared by van der Waerden’s nonparametric test and categorical variables by chi-square test. When the
overall P value was <0.05, post hoc comparisons between groups were performed. Means in the same row without a common letter differ (P < 0.05 with the Tukey–Kramer
adjustment). Control, placebo; LAZ, length-for-age z score; MNP, daily multiple micronutrient powder; PZ, daily preventive zinc tablets; TZ, therapeutic dispersible zinc tablets;
WAZ, weight-for-age z score; WLZ, weight-for-length z score.
2Anthropometry measurements: n for PZ = 121 (All = 511).
3Maternal age: n for control = 130, TZ = 115, MNP = 133, and PZ = 117 (All = 495).
4Maternal BMI: n for control = 112, TZ = 93, MNP = 96, and PZ = 96 (All = 397).
5Plasma zinc adjusted for inflammation using plasma C-reactive protein and α-1-acid glycoprotein as described in reference 21.
dropped from analysis.All variables were then assessed for conformance
to the Gaussian distribution and transformed if needed for analysis. For
use in figures, untransformed group means were estimated by back-
transforming the group means of transformed variables. Means of
endline values were compared with ANCOVA (SAS GLM procedure),
controlling for the baseline value of the outcome, child age and sex,
district, month of enrollment, and zinc status [below, or above or equal
to, the median baseline plasma zinc concentration (54.2 mg/dL) from
all study participants, or CRP- and AGP-adjusted plasma zinc (21)
(56.0 mg/dL), considered in separate models]. Pairwise comparisons of
all group means to one another were adjusted with the Tukey–Kramer
test. Zinc status (i.e., baseline plasma zinc concentration below the
median), child sex, and child age at enrollment were tested individually
as possible effect modifiers by including interaction terms in the model,
and subgroupmeans were estimatedwhen the P value for the interaction
term was <0.20.
Results
Demographic characteristics and nutritional status
The mean ± SD age of infants was 15.6 ± 5.1 mo at baseline
and 52.3% of participants were male (Table 1). The prevalence
of stunting and underweight was high, at 36.8% and 25.6%,
respectively, whereas the prevalence of wasting was 6.8%.
The mean ± SD plasma zinc concentration (not adjusted for
inflammation) at baseline was 57.4 ± 11.9 μg/dL, with 77.5%
of participants being categorized as deficient using the cutoff
of 65 μg/dL (24). Plasma zinc concentration did not differ
by treatment group at baseline. The PZ and MNP treatments
caused a significant increase in plasma zinc concentration by
the end of the study, with mean plasma zinc at endline being
significantly greater in these 2 groups than in the control and
TZ groups (Table 2). Similarly, the percentages of infants with
zinc deficiency at endline were lower in the PZ andMNP groups
than in the control and TZ groups.
T-cell cytokines
The concentration of IL-2 was measured as a key growth
cytokine for T-cells, IL-10 was measured as an important
regulatory cytokine, and IFN-γ , IL-13, and IL-17 were
measured as markers for Th1, Th2, and Th17 CD4 T-cell
subsets, respectively. No differences were seen between the
treatment groups for any of the T-cell cytokines at endline, nor
was any interaction seen between treatment group and baseline
zinc status (Figure 1). Supplemental Table 1 shows unadjusted
baseline and endline concentrations of these cytokines. The
concentrations of IL-2 and IL-17 did not differ from baseline
to endline, whereas the concentrations of the other 3 cytokines
decreased (without adjustment for covariates).
TABLE 2 Endline characteristics of total study population (All) and each treatment group1
Characteristic All Control TZ MNP PZ P value
Length-for-age z score − 1.83 ± 1.05 − 1.55 ± 1.02 − 2.00 ± 1.00 − 1.90 ± 1.01 − 1.90 ± 1.14 0.30
Weight-for-age z score − 1.58 ± 0.98 − 1.32 ± 0.94 − 1.69 ± 1.05 − 1.67 ± 0.95 − 1.66 ± 0.94 0.54
Weight-for-length z score − 0.86 ± 0.88 − 0.73 ± 0.81 − 0.87 ± 0.96 − 0.90 ± 0.93 − 0.94 ± 0.83 0.97
Plasma zinc, mg/dL2 61 ± 16 56.8 ± 11.9a 58.4 ± 14.5a 63.6 ± 15.9b 67.2 ± 18.1b <0.0001
Plasma zinc < 65 mg/dL2 68.6 (349) 80.6 (108)a 78.3 (94)a 61.5 (83)b 53.3 (64)b <0.0001
1Values are means ± SDs or % (n). The number of study participants is indicated in Table 1. The P values indicate statistical significance for differences between treatment
group means. The analysis was adjusted for baseline value of each variable, sex, district, age, season, and baseline plasma zinc (above/below median) as described in the
Methods. Percentages were compared by chi-square test. When the overall P value was <0.05, post hoc comparisons between groups were performed. Means in the same
row without a common letter differ (P < 0.05 with the Tukey–Kramer adjustment). Control, placebo; MNP, daily multiple micronutrient powder; PZ, daily preventive zinc tablets;
TZ, therapeutic dispersible zinc tablets.
2Plasma zinc adjusted for inflammation using plasma C-reactive protein and α-1-acid glycoprotein as described in reference 21.
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FIGURE 1 Endline cytokine concentrations of 4 treatment groups. Whole blood from each treatment group (C, n = 134; TZ, n = 120; MNP,
n = 136; PZ, n = 122) was stimulated with anti-CD3 plus anti-CD28 antibodies (A–E) or with bacterial LPS (F–I). Data are represented as back-
transformed means and estimated SEs. Means are adjusted for baseline value of each variable, sex, district, age, season, and baseline plasma
zinc (above or equal to, and below, the median). P values indicate statistical significance for differences between treatment group means (P) and
significance of interaction with categorical plasma zinc status (Pixn). C, control; MNP, daily multiple micronutrient powder; PZ, daily preventive
zinc tablets; TZ, therapeutic dispersible zinc tablets.
LPS-stimulated cytokines
The concentration of IL-10 was measured as a regulatory
cytokine that can be produced by innate immune cells (e.g.,
monocytes) that would be stimulated by LPS, whereas IL-
1β, IL-6, and TNF-α were measured as key proinflammatory
cytokines. There was no treatment effect on these cytokines,
nor any interaction with baseline zinc status (Figure 1).
Supplemental Table 2 shows the unadjusted baseline and
endline concentrations. The concentration of IL-1β decreased
over time, whereas the concentrations of the other cytokines
increased.
T-cell concentrations
Concentrations of total and memory CD4 T-cells, total and
memory CD8 T-cells, and Treg cells were measured by flow
cytometry (Supplemental Figure 1). There was no treatment
effect on these cell types, nor any interactions with baseline zinc
status (Figure 2). Supplemental Table 3 shows the unadjusted
baseline and endline concentrations. The concentrations of
total CD4 and CD8 T-cells decreased over time, as did the
concentration of memory CD8, but not CD4, T-cells. The
concentration and percentage of Treg cells both decreased over
time.
Leukocyte and platelet concentrations
Lymphocyte, monocyte, neutrophil, eosinophil, basophil, and
platelet concentrations were measured and regression anal-
ysis found a significant treatment effect on lymphocyte
concentrations (P = 0.032) but not for the other leukocyte
variables (Figure 3). Endline lymphocyte concentrations were
significantly lower in the PZ group than in the control group,
whereas the other 2 treatment groups were intermediary and
did not differ significantly from either the PZ or the control
group. A very similar, but nonsignificant, trend was seen
for total lymphocytes (the sum of lymphocytes and atypical
lymphocytes, which were present at very low concentrations)
(P = 0.081) (Figure 3A, B). Significant interactions of treatment
with baseline zinc status were seen for monocytes, eosinophils,
and basophils (Figure 3C, F, G). Stratified post hoc comparisons
found significant differences in eosinophil concentrations
between the control and PZ groups, as well as between the TZ
and PZ groups, for infants with baseline plasma zinc below (but
not above) the median concentration (Figure 4). No significant
differences were seen between means in such stratified analyses
for basophils or monocytes (Figure 4). Supplemental Table
4 shows unadjusted baseline and endline concentrations of
leukocytes and platelets, whereas Supplemental Table 5 shows
unadjusted concentrations of eosinophils, basophils, and mono-
cytes divided by baseline zinc status. Eosinophil concentrations
were somewhat higher than expected for healthy children, with
33% (135 of 410) of children having mild eosinophilia, using a
cutoff of ≥500 eosinophils/μL, whereas 6.8% (28 of 410) had
moderate eosinophilia (≥1500 eosinophils/μL), a concentration
that would warrant clinical evaluation if it were chronic (25).
Neutrophil concentrations increased from baseline to endline,
whereas platelets and all other leukocyte variables decreased
over time.
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FIGURE 2 Endline T-cell concentrations of 4 treatment groups. Peripheral blood from each treatment group (C, n = 134; TZ, n = 120; MNP,
n = 136; PZ, n = 122) was stained for T-cell surface markers and analyzed data are represented as back-transformed means and estimated SEs
for total (A, B) and memory (D, E) CD4 and CD8 T-cell concentrations and for Treg cell concentration (C) and percentage (F). Means are adjusted
for baseline value of each variable, sex, district, age, season, and baseline plasma zinc (above or equal to, and below, the median). P values
indicate statistical significance for differences between treatment group means (P) and significance of interaction with categorical plasma zinc
status (Pixn). C, control; MNP, daily multiple micronutrient powder; PZ, daily preventive zinc tablets; TZ, therapeutic dispersible zinc tablets.
Adjusting for baseline anthropometric status
In an additional, exploratory, analysis for all immunology
variables, baseline anthropometric variables (WLZ and LAZ)
were included in the regression model to adjust for group
imbalance and, as a result, a significant overall treatment effect
was seen for platelets (P = 0.032) and the TZ group was found
to be significantly lower than the control group (P = 0.017),
with the other 2 groups being intermediate. The adjusted,
back-transformed mean ± SE values at endline for the control,
TZ, MNP, and PZ groups were 422 ± 10, 387 ± 10, 408 ± 10,
and 419 ± 11/mL, respectively.
Discussion
The primary dependent variables in the present study were
cytokines produced after LPS stimulation as an index of the
responsiveness of innate immune cells, T-cell cytokines as an
index of T-cell responsiveness, and concentrations of T-cells
in peripheral blood. No effect was seen of the different zinc
supplementation regimens on these endpoints, relative to the
control intervention. Our primary focus was on the 2 daily zinc
supplementation regimens, PZ and MNP, which both increased
plasma zinc and decreased the prevalence of zinc deficiency over
the course of the study in this subset of study participants, as was
also reported by the parent study using a slightly larger sample
size (21). Thus, our finding of no effect of these interventions
on the selected immunologic endpoints demonstrates that these
measures of innate and adaptive immunity did not improve
over a 9-mo period during which zinc status was improved.
Because the children in this study had a high prevalence of zinc
deficiency, the failure to see a response is likely not due to an
absence of zinc deficiency at baseline. In addition, we included
an interaction term to evaluate the effect of the interventions on
children stratified by baseline zinc status and saw no differential
effect, strengthening our conclusion that these indicators are
not responsive to improvements of zinc status. However, at the
end of the study >50% of participants in the TZ and MNP
groups were still zinc deficient, using the cutoff of<65μg/dL for
plasma zinc, which leaves open the possibility that a further
improvement in zinc status might have produced a change in
these variables.
Previous randomized trials of zinc supplementation to
children have examined effects on T-cell concentration or
function. Treatment of marasmic infants in Chile with zinc
(n= 16, 2 mg · kg−1 · d−1; n= 16 placebo) for 90 d increased the
T-cell proliferative response to the mitogen phytohemagglutinin
(PHA), suggesting increased T-cell concentrations or prolifera-
tive ability (26). This study in severe malnutrition (marasmus)
is not directly comparable with ours, which excluded severe
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FIGURE 3 Endline leukocyte and platelet concentrations of 4 treatment groups. Complete blood count data were obtained from peripheral
blood of each treatment group (C, n = 134; TZ, n = 120; MNP, n = 136; PZ, n = 122) and analyzed data are represented as back-transformed
means and estimated SEs for lymphocytes (A), atypical lymphocytes (B), monocytes (C), platelets (D), neutrophils (E), eosinophils (F), and
basophils (G). Means are adjusted for baseline value of each variable, sex, district, age, season, and baseline plasma zinc (above or equal to, and
below, the median). P values indicate statistical significance for differences between treatment group means (P) and significance of interaction
with categorical plasma zinc status (Pixn). Means with different letters have significantly different concentrations (P < 0.05 with Tukey–Kramer
adjustment for multiple comparisons). C, control; MNP, daily multiple micronutrient powder; PZ, daily preventive zinc tablets; TZ, therapeutic
dispersible zinc tablets.
malnutrition (WLZ and WAZ < 3 z scores). A community-
based trial in India compared 10 mg Zn daily (20 mg during
diarrhea episodes; n = 38) with placebo (n = 48) for 120 d and
found a relative increase in the percentage of CD4 (but not CD8)
T-cells, but with no results reported for T-cell concentrations
(27). A short treatment study of Bangladeshi children with
Shigella dysentery used 20 mg Zn/d plus multivitamins for 2
wk (n = 28) compared with placebo (n = 28) and found an
increase in the T-cell proliferative response to PHA with no
effect on production of IFN-γ from the same cultures (28),
although this study differs from ours in its short duration
and treatment of children with dysentery during recovery. A
longer study (29) began with treatment of Bangladeshi children
with diarrhea due to enterotoxigenic E. coli with 20 mg Zn/d
for all children, but continued after recovery with random
assignment of children to 10 mg Zn/d (n = 74) or placebo
for 3 mo (n = 74). The study examined the ratio of naïve
(CD45RA+) to memory (CD45RO+) total or CD4 T-cells at
baseline and endline, finding no effect (29). An intervention
study in Mexican-American children supplemented with 20 mg
Zn plus multiple micronutrients 5 d/wk for 10 wk (n = 27),
as compared with placebo recipients (n = 27), saw a relative
increase in the ratio of naïve to memory CD4 T-cells in the zinc
group, as well as an increased production of IFN-γ by PHA-
stimulated peripheral blood mononuclear cell cultures, and a
decrease in IL-10 from the same cultures (30). In summary,
these studies showed inconsistent effects on measures of T-
cell concentration and function. Where significant differences
were seen between the placebo and zinc intervention (typically
10 or 20 mg/d), the tendency was to see an increase in naïve
or total CD4 T-cell concentrations, or an increase in T-cell
proliferation or production of the T-cell cytokine IFN-γ (in 1
study). The latter 2 results could both result from increased
T-cell concentrations in peripheral blood, because the assays
were not standardized for T-cell concentrations. We predicted
similar increases in total CD4 T-cell concentrations and in
CD4 Treg cell concentrations in the present study, but found
no differences. Our daily doses of zinc (7 mg/d in the PZ
group and 10 mg/d in the MNP group) were similar to those
of these previous studies, whereas our sample size per group
(∼100) was larger and the duration of our study (9 mo) was
longer than these previous studies. We thus feel that the null
outcome of our study for these T-cell endpoints is not due to an
inadequate treatment dose, a small sample size, or inadequate
study duration, but is likely due to a lack of effect of treating zinc
deficiency on this aspect of immune function in this population.
We were not able to examine T-cell proliferation in the present
study owing to the small volume of blood that was available
and thus we do not know if the measure of T-cell function may
have been affected.
In addition to these comparisons,we also examined the effect
of these zinc interventions on peripheral blood lymphocyte,
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FIGURE 4 Endline eosinophil (A), basophil (B), and monocyte
(C) concentrations of 4 treatment groups by baseline zinc status
(above/below the median plasma zinc concentration). Complete blood
count data of these cell types from peripheral blood were analyzed
for a significant interaction of zinc status with treatment group (C,
n = 134; TZ, n = 120; MNP, n = 136; PZ, n = 122). The data are
represented as back-transformed means and estimated SEs. Means
are adjusted for baseline value of each variable, sex, district, age,
season, and baseline plasma zinc (above or equal to, and below,
the median). P values indicate statistical significance for differences
between treatment group means within zinc-status subgroups (P).
Means with different letters have significantly different concentrations
(P< 0.05with Tukey–Kramer adjustment for multiple comparisons). C,
control; MNP, daily multiple micronutrient powder; PZ, daily preventive
zinc tablets; TZ, therapeutic dispersible zinc tablets.
monocyte, neutrophil, eosinophil, basophil, and platelet concen-
trations. Among these secondary endpoints,we saw a significant
decrease in lymphocyte concentration (which includes both T
and B cells) in the PZ group relative to the control group
in the overall study population. The mean total lymphocyte
concentrations in our study subjects at baseline (6–23 mo of
age) and endline (∼9 mo later) are similar to recent reports for
healthy Chinese children at these ages, a period over which a
decline of ∼10–20% would be expected (31), as was seen in the
present study. The health implication, if any, for the relatively
greater decrease in the PZ than in the control group is uncertain.
Because T-cell concentrations did not decrease in response to
zinc treatment, one can speculate that B-cell concentrations
did decrease in response to PZ supplementation, but we have
no way to assess that retrospectively. Two recent studies have
identified 2 different zinc transporters as having key roles in
B-cell biology (32, 33), suggesting that further examination of
this cell type is warranted. Another interpretation of this result
is that zinc may have dampened a mild lymphocytosis in this
population, perhaps resulting from undiagnosed infections, but
this is also speculation.
In addition to a decrease in lymphocytes, we saw a decrease
in eosinophil concentration in the PZ group relative to the
control group in children with low zinc status (below the overall
median plasma zinc concentration) at baseline. This finding is
similar to results seen in 2 rodent studies which found that zinc
supplementation decreased pulmonary eosinophilia in models
of allergic asthma (34, 35). A human study of relevance has
also been reported: infants with chronic wheeze, a condition
consistent with a risk of atopic asthma, were found to have
poor zinc status (as indicated by low hair zinc concentrations)
relative to other children, suggesting an association of zinc
deficiency with atopic disease, although no association was seen
with eosinophil concentrations (36). Helminth infections also
induce eosinophilia and in a rodent model ofHeligmosomoides
polygyrus infection, investigators found that zinc deficiency
was associated with lower rather than higher blood eosinophil
concentrations, although the effect of intervening with zinc
supplements was not examined (37, 38). Thus, the literature
does not show a consistent association of zinc status with
eosinophilic inflammation, but the present study suggests that
future work on this topic may be of interest.
Children in our study had an unexpectedly high prevalence
of eosinophilia, with 33% showing evidence of at least mild
eosinophilia, even though they were apparently healthy at the
time of blood collection (i.e., absence of reported diarrhea or
measured fever within 24 h of the blood sample collection).
Eosinophilia is relatively uncommon but can result from
intestinal helminth infections (39) as well as other conditions
(40). Even asymptomatic intestinal helminth infections can
cause eosinophilia, as shown by a recent study among
asymptomatic adults with Strongyloides stercoralis infection
in south India where higher eosinophil concentrations were
seen in asymptomatic, infected individuals (geometric mean:
550 eosinophils/μL) than in asymptomatic, uninfected controls
(geometric mean: 281 eosinophils/μL) (41). Although we do
not have diagnostic information on helminth infections for
the children in our study population, a recent study in
another rural area of Laos found high prevalence rates of
intestinal helminths in a community-based study of children
and adults (≥2 y; n = 574), with infection rates of 87%
for hookworm, 33% for Trichuris trichiura, and 10% for
Ascaris lumbricoides. These infections can cause eosinophilia
(39) and if such infections were common in our study
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population this could explain the high levels of eosinophilia.
If this were true, one could then speculate that the zinc
treatment might have reduced eosinophil concentrations by
helping to clear or reducing the severity of intestinal helminth
infections. Although the aforementioned rodent studies (37,
38) indicate that zinc deficiency decreases eosinophilia in H.
polygyrus infection, the study did not examine effects of zinc
supplementation on resolution of infection or eosinophilia,
leaving open the possibility that zinc may be beneficial for
intestinal helminth infections in humans. In addition, helminth
infections themselves can affect both innate and adaptive
immune function (42) and results of a zinc intervention trial
such as this might differ between children with andwithout such
infections.
Strengths of the present study include its large sample size
and its setting in a population with a high prevalence of zinc
deficiency and close proximity to laboratory facilities suitable
for analysis of immune function. A shortcoming of the study
is that a majority of the participants remained zinc-deficient
at the end of the trial, raising the question of whether a
higher dose of zinc might have produced different results. The
apparent effect of preventive zinc (PZ group), given daily as
a 7-mg supplement, on total lymphocytes (perhaps on B cells)
and on eosinophils (possibilities that were discussed above), is
interesting and suggests that further examination of the effect of
zinc treatment on these cell subsets may prove to be fruitful in
identifying an immunologic indicator that is responsive to zinc
supplementation.
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